Cell Source, Inc. (ticker: CLCS) is an OTC-listed pharma company. DredgeCap's structured extraction of CLCS's SEC filings surfaces 16 active risk signals, including 14 late-filing signals, 1 auditor-change signal, and 1 delisting/deregistration signal. CLCS reported no tagged revenue in revenue and -$1.48M for the period ending 2025-03-31, with operating cash flow of -$600K. Cash and equivalents stood at $1K (up 5291.3% year-over-year). Total assets of $292K are exceeded by total liabilities of $20.43M. Each signal on this page is sourced verbatim from the underlying SEC filing. Use the tabs above to drill into auditor history, going-concern citations, dilution mechanics, cash runway, and the full risk-flag inventory.
CLCS SEC Filings
Full cached SEC EDGAR filing history for CLCS, grouped by form type and sorted newest-first within each group. 0 filings across 0 form types.
Filings sourced verbatim from SEC EDGAR submissions metadata. “Structured” links route to DredgeCap's per-filing renderer (XBRL-backed financials + cited highlights) when available; the EDGAR link always points to the canonical accession index on sec.gov.